Vanguard Group Inc Xilio Therapeutics, Inc. Transaction History
Vanguard Group Inc
- $6.44 Trillion
- Q3 2025
A detailed history of Vanguard Group Inc transactions in Xilio Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,255,692 shares of XLO stock, worth $878,984. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,255,692
Previous 1,151,023
9.09%
Holding current value
$878,984
Previous $782,000
36.45%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding XLO
# of Institutions
35Shares Held
11MCall Options Held
0Put Options Held
0-
Bain Capital Life Sciences Investors, LLC Boston, MA4.57MShares$3.2 Million1.25% of portfolio
-
River Vest Venture Management LLC St. Louis, MO1.44MShares$1.01 Million16.6% of portfolio
-
Morgan Stanley New York, NY962KShares$673,3410.0% of portfolio
-
Aju Ib Investment Co., Ltd. Seoul, M5668KShares$467,4190.49% of portfolio
-
Geode Capital Management, LLC Boston, MA329KShares$230,2800.0% of portfolio
About Xilio Therapeutics, Inc.
- Ticker XLO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 27,471,600
- Market Cap $19.2M
- Description
- Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine prog...